Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Chief Innovation & Technology Officer at Monosol Rx
A. Mark Schobel has 41 years of experience in the pharmaceutical industry ranging from dosage form and technology development to strategic global intellectual property (IP) portfolio development and implementation. Mark has been awarded 21 patents and has several patents pending most of which are predominately in the film drug delivery space. Mark pioneered the first oral therapeutic films to be introduced into the US market at Novartis and is considered a leading pharmaceutical film expert. Mark was the CEO of MonoSol Rx LLC for the company’s first 9 years where he developed the first Rx sublingual, lingual and drug combination films to be approved by the FDA. He was responsible for the successful development of Suboxone SL Film and Zuplenz OS Film. Mark now concentrates his efforts on global IP development, prosecution, protection and litigation while identifying or developing technologies that can complement and/or enable film drug delivery for enhanced therapeutics and pharmaceutical utility.